Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

3 Best Dividend ETFs to Buy for Passive Income

High-yield dividend ETFs, such as SCHD, offer investors the ability to create a passive income stream for life at a relatively low cost.

Barchart

The FTC should embrace proactive problem-solving

The legal precedent would strongly discourage companies from trying to solve perceived problems with proposed transactions.

Fortune

Competition cop Lina Khan’s antitrust overreach is hurting U.S. competitiveness–and destroying billions of dollars in value

Antitrust overreach is hurting America's global competitiveness, with the FTC calculating industry concentration on a purely domestic basis.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

StockNews.com

Amgen cuts Horizon Therapeutics jobs at Deerfield office after acquisition

350 people will be laid off, many of them at Horizon’s U.S. base in Deerfield.

Chicago Sun-Times

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

All in: Drugmakers say yes, they'll negotiate with Medicare on price, so reluctantly

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

WEKU

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

StockNews.com

Alphabet's Wing CFO Shannon Nash shares her unique path to the C-suite

Nash, who is also an award-winning film producer, names Debbie Allen as one of her greatest mentors.

Fortune

The history of weight loss drugs

"It is no wonder demand for weight-loss drugs continues to soar"

Salon

Ozempic is in the spotlight but it's just the latest in a long and strange history of weight-loss drugs

Losing weight conveniently, cheaply, safely. That’s been the holy grail of weight-loss ever since 19th century English undertaker and weight-loss celebrity William Banting’s 1863 Letter on Corpulence spruiked his “miraculous” method of slimming down.

The Conversation

Stock Market Today: Dow Outperforms as Amgen, Boeing Gain Ground

The main benchmarks closed higher ahead of this week's key inflation update.

Kiplinger

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Radio France Internationale

Jailed Dutch-Chinese scientist 'forgotten' by his country and company

Dr Zhang Mingqiang is in cell number 204 of Shanghai’s notorious Qingpu prison – sentenced to six years for spying. He worked for US pharmaceutical giant Amgen in charge of research and development at their Asian operations. Caught in the crossfire between Beijing, the US and the EU, Zhang and…

Tribune News Service

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Barchart

Stocks Undercut as Little Progress is seen in U.S. Debt Ceiling Talks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up +0.09%. Stock indexes Tuesday settled mixed, with the Dow Jones...

The Independent UK

Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon

Federal regulators are suing to block biotech drug developer Amgen’s more than $26 billion deal for Horizon Therapeutics

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Stocks Mixed as Debt Ceiling Talks Resume

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. U.S. stocks this morning are mixed, with the Dow...

Barchart

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Tribune News Service

The drug company that prospered without creating any drugs

The new drug looked so promising — except for that one warning sign.

Fortune

How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own

Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

StockNews.com

3 High-Quality Stocks to Add to Your Watchlist Now

Despite the bank failures, the Fed will likely keep raising interest rates to bring inflation down. This is expected to keep the stock market under pressure. Amid this backdrop, it could be wise for investors to add high-quality stocks Visa (V), Amgen (AMGN), and Box (BOX) to their watchlist. Keep…

StockNews.com

3 Dow Stocks to Buy More of in March 2023

With the Fed keen on further interest rate hikes this year, the stock market will likely remain under pressure. Amid this backdrop, it could be wise for investors to buy fundamentally strong Dow stocks like Verizon Communications (VZ), Amgen (AMGN), and International Business Machines (IBM). Read more….

Tribune News Service

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

1 … 3 4 5 6

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.